In ER-negative breast tumors, we found that high SERPINB2 levels are associated with a low tumor stage (Fig. 5A) and an improved distant metastasis-free survival (DMFS) (Fig. 5B-C). This evidence concerns the gene SERPINB2 and neoplasm.